Lectin-directed enzyme activated prodrug therapy (LEAPT): Synthesis and evaluation of rhamnose-capped prodrugs

Journal of Drug Targeting

Volumn 18, Issue 10, 2010, Pages 794-802

  Garnier, Philippe ^a   Wang, Xiang Tao ^a   Robinson, Mark A ^a   Van Kasteren, Sander ^a   Perkins, Alan C ^b   Frier, Malcolm ^b   Fairbanks, Antony J ^a,c   Davis, Benjamin G ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b QUEEN S MEDICAL CENTRE   (United Kingdom)

^c UNIVERSITY OF CANTERBURY   (New Zealand)

Author keywords

5 fluorouracil; carbohydrates; d galactose; doxorubicin; enzyme release; l rhamnose; Lectins; prodrug

Indexed keywords

(2,3,4 TRI O ACETYL ALPHA LEVO RHAMNOPYRANOSYL) 4 NITROPHENYL CARBONATE; 1,2,3,4 TETRA O ACETYL LEVO RHAMNOSE; 2,3,4 TRI O ACETYL LEVO RHAMNOSE; ACETOXY N (2,3,4 TRI O ACETYL ALPHA LEVO RHAMNOPYRANOSYLOXYCARBONYL) METHYLAMINE; DOXORUBICIN; FLUOROURACIL; N (2,3,4 TRI O ACETYL ALPHA LEVO RHAMNOPYRANOSYLOXYCARBONYL) (5 FLUORO 2,4 DIOXO 1,2,3,4 TETRAHYDROPYRIMIDIN 1 YL) METHYLAMINE; N (2,3,4 TRI O ACETYL ALPHA LEVO RHAMNOPYRANOSYLOXYCARBONYL) GLYCINE; N (ALPHA LEVO RHAMNOPYRANOSYOXYCARBONYL) (5 FLUORO 2,4 DIOXO 1,2,3,4 TETRAHYDROPYRIMIDIN 1 YL) METHYLAMINE; PRODRUG; RHAMNOSE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; BLOOD; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG RELEASE; DRUG STABILITY; ENZYME PRODRUG THERAPY; LECTIN DIRECTED ENZYME ACTIVATED PRODRUG THERAPY; LIVER CANCER; MALE; NONHUMAN; PRIORITY JOURNAL; RABBIT;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; ANTIMETABOLITES, ANTINEOPLASTIC; DOXORUBICIN; DRUG DELIVERY SYSTEMS; FLUOROURACIL; GLYCOSIDE HYDROLASES; LECTINS; LIVER; MALE; PRODRUGS; RABBITS;

EID: 78149420113     PISSN: 1061186X     EISSN: 10292330     Source Type: Journal    
DOI: 10.3109/1061186X.2010.529909     Document Type: Article

References (24)

1. Bagshawe KD. (1994). Antibody-Directed Enzyme Prodrug Therapy (ADEPT). J Controlled Release, 28, 187-193.
2. Blum RH, Carter SK. (1974). Adriamycin. A new anticancer drug with significant clinical activity. Ann Intern Med, 80, 249-259.
3. Davis BG, Robinson MA. (2002). Drug delivery systems based on sugar-macromolecule conjugates. Curr Opin Drug Discov Devel, 5, 279-288.
4. Dwek RA. (1996). Glycobiology: Toward Understanding the Function of Sugars. Chem Rev, 96, 683-720.
5. Eisenberg C, Seta N, Appel M, Feldmann G, Durand G, Feger J. (1991). Asialoglycoprotein receptor in human isolated hepatocytes from normal liver and its apparent increase in liver with histological alterations. J Hepatol, 13, 305-309.
6. Fisher E, Bergmann M, Rabe A. (1920). Ü;ber Acetobrom-rhamnose und ihre Verwendung zur Synthese von Rhamnosiden. Chem Ber, 53, 2362-2388.
7. Gamblin DP, Scanlan EM, Davis BG. (2009). Glycoprotein synthesis: an update. Chem Rev, 109, 131-163.
8. Johnston PG, Kaye S. (2001). Capecitabine: a novel agent for the treatment of solid tumors. Anticancer Drugs, 12, 639-646.
9. Launchbury AP, Habboubi N. (1993). Epirubicin and doxorubicin: a comparison of their characteristics, therapeutic activity and toxicity. Cancer Treat Rev, 19, 197-228.
10. Lee YC, Townsend RR, Hardy MR, Lö;nngren J, Arnarp J, Haraldsson M, Lö;nn H. (1983). Binding of synthetic oligosaccharides to the hepatic Gal/GalNAc lectin. Dependence on fine structural features. J Biol Chem, 258, 199-202.
11. Lefrak EA, Pitha J, Rosenheim S, Gottlieb JA. (1973). A clinicopathologic analysis of adriamycin cardiotoxicity. Cancer, 32, 302-314.
12. Lis H, Sharon N. (1998). Lectins: Carbohydrate-Specific Proteins That Mediate Cellular Recognition. Chem Rev, 98, 637-674.
13. Longley DB, Harkin DP, Johnston PG. (2003). 5-fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer, 3, 330-338.
14. Madec-Lougerstay R, Florent JC, Monneret C. (1999). Synthesis of selfimmolative glucuronide spacers based on aminomethylcarbamate. Application to 5-fluorouracil prodrugs for antibody-directed enzyme prodrug therapy. J Chem Soc, Perkin Trans, 1, 1369-1375.
15. Richards JC, Leitch RA. (1989). Elucidation of the structure of the Pasteurella haemolytica serotype T10 lipopolysaccharide O-antigen by n.m.r. spectroscopy. Carbohydr Res, 186, 275-286.
16. Robinson MA, Charlton ST, Garnier P, Wang XT, Davis SS, Perkins AC, Frier M, Duncan R, Savage TJ, Wyatt DA, Watson SA, Davis BG. (2004). LEAPT: lectin-directed enzyme-activated prodrug therapy. Proc Natl Acad Sci USA, 101, 14527-14532.
17. Russell D, Oldham NJ, Davis BG. (2009). Site-selective chemical protein glycosylation protects from autolysis and proteolytic degradation. Carbohydr Res, 344, 1508-1514.
18. Sim MM, Kondo H, Wong CH. (1993). Synthesis and use of glycosyl phosphites - an effective route to glycosyl phosphates, sugar nucleotides, and glycosides. J Am Chem Soc, 115, 2260-2267.
19. Singh Y, Palombo M, Sinko PJ. (2008). Recent trends in targeted anticancer prodrug and conjugate design. Curr Med Chem, 15, 1802-1826.
20. Smedsrød B, De Bleser PJ, Braet F, Lovisetti P, Vanderkerken K, Wisse E, Geerts A. (1994). Cell biology of liver endothelial and Kupffer cells. Gut, 35, 1509-1516.
21. Varki A. (1993). Biological roles of oligosaccharides: all of the theories are correct. Glycobiology, 3, 97-130.
22. Weis WI, Drickamer K. (1996). Structural basis of lectin-carbohydrate recognition. Annu Rev Biochem, 65, 441-473.
23. Wentworth P, Datta A, Blakey D, Boyle T, Partridge LJ, Blackburn GM. (1996). Toward antibody-directed abzyme prodrug therapy, ADAPT: carbamate prodrug activation by a catalytic antibody and its in vitro application to human tumor cell killing. Proc Natl Acad Sci USA, 93, 799-803.
24. Zhang H, Ma Y, Sun XL. (2010). Recent developments in carbohydratedecorated targeted drug/gene delivery. Med Res Rev, 30, 270-289.